SPUTNIK-V REACTOGENICITY AND IMMUNOGENICITY IN THE BLOOD AND MUCOSA: A PROSPECTIVE COHORT STUDY

Simple item page
dc.contributor.authorYegorov, Sergey
dc.contributor.authorKadyrova, Irina
dc.contributor.authorNegmetzhanov, Baurzhan
dc.contributor.authorKolesnikova, Yevgeniya
dc.contributor.authorKolesnichenko, Svetlana
dc.contributor.authorKorshukov, Ilya
dc.contributor.authorBaiken, Yeldar
dc.contributor.authorMatkarimov, Bakhyt
dc.contributor.authorMiller, Matthew S.
dc.date.accessioned2023-02-17T10:21:11Z
dc.date.available2023-02-17T10:21:11Z
dc.date.issued2022
dc.description.abstractSputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID- 19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine’s performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. We observed that most of the reported adverse events were mild-to-moderate injection site or systemic reactions, no severe or potentially life-threatening conditions were reported, and dose 1 appeared to be more reactogenic than dose 2. The seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization was 83% post-dose 1, increasing to 98% post-dose 2, with the largest relative increase observed in participants without prior COVID- 19 exposure. Dose 1 boosted nasal S-IgG and S-IgA, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Overall, Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal. Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine’s effects on systemic immunology.en_US
dc.identifier.citationYegorov, S., Kadyrova, I., Negmetzhanov, B., Kolesnikova, Y., Kolesnichenko, S., Korshukov, I., Baiken, Y., Matkarimov, B., Miller, M. S., Hortelano, G. H., & Babenko, D. (2022). Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-17514-3en_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/6963
dc.language.isoenen_US
dc.publisherScientific Reportsen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectType of access: Open Accessen_US
dc.subjectSputnik‑Ven_US
dc.subjectCOVID- 19 vaccineen_US
dc.titleSPUTNIK-V REACTOGENICITY AND IMMUNOGENICITY IN THE BLOOD AND MUCOSA: A PROSPECTIVE COHORT STUDYen_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41598-022-17514-3.pdf
Size:
3.27 MB
Format:
Adobe Portable Document Format
Description:
article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Articles